South San Francisco, CA, United States of America

Teemu Tapani Junttila

USPTO Granted Patents = 2 

Average Co-Inventor Count = 5.8

ph-index = 1


Location History:

  • South San Francisco, CA (US) (2024)
  • San Mateo, CA (US) (2024)

Company Filing History:


Years Active: 2024

Loading Chart...
2 patents (USPTO):

Title: The Innovative Contributions of Teemu Tapani Junttila in Targeted Cancer Therapies

Introduction

Teemu Tapani Junttila, based in South San Francisco, California, is a notable inventor in the field of biopharmaceuticals. With a strong focus on cancer treatments, he holds two significant patents that contribute to advancements in targeted therapies. His work has potential implications for improving the efficacy of cancer treatments, making him a valuable asset in the medical research community.

Latest Patents

Teemu Tapani Junttila's latest patents include groundbreaking innovations. The first patent, titled “HER2-targeting antigen binding molecules comprising 4-1BBL,” relates to Her2 targeting 4-1BB agonists. This invention particularly focuses on 4-1BBL trimer-containing antigen binding molecules, which include at least one antigen binding domain capable of specific binding to Her2. These molecules are designed for the treatment of cancer and can be used in combination with T-cell activating anti-CD3 bispecific antibodies.

The second patent, “Agonistic CD28 antigen binding molecules targeting Her2,” presents Her2-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28. It details methods for their production, pharmaceutical compositions that contain these antibodies, and various methods of using them in therapeutic applications.

Career Highlights

Teemu's career at Hoffmann-La Roche Inc. has enabled him to translate his innovative ideas into practical solutions for complex medical challenges. His expertise in cancer immunotherapy has been instrumental in the development of cutting-edge treatments that target specific cancer biomarkers, ultimately aiming to improve patient outcomes.

Collaborations

Throughout his career, Teemu has collaborated with esteemed colleagues such as Christian Klein and Stephan Gasser. These collaborations have fostered an environment of innovation and discovery, allowing the team to combine their knowledge and skills to push the boundaries of cancer therapies.

Conclusion

Teemu Tapani Junttila's work and patents are reshaping the future of cancer treatment through targeted therapies. His contributions at Hoffmann-La Roche Inc. highlight the importance of innovation and collaboration in the medical field. By focusing on the advancement of Her2-targeted therapies, Teemu continues to pave the way for more effective cancer treatments, benefiting both the scientific community and patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…